India’s Rx Policy Shifts Could Spark Turf Wars Within Government
Draft appears set for rocky path ahead; Pink Sheet highlights five controversial elements ahead of Aug 30 stakeholders meeting.
You may also be interested in...
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.
An Indian Parliamentary panel has recommended a "blanket ban" on foreign direct investment (FDI) in brownfield pharmaceutical projects in the country, claiming "danger" to health and intellectual property rights aspects arising from such investments including access and affordability of medicines, as well as the "elbowing" out of the domestic industry and undue pressures on TRIPS arrangements.